Hemab Therapeutics Holdings, Inc. Common Stock (COAG) Earnings Analysis
Hemab Therapeutics Holdings, Inc. Common Stock (COAG) next reports earnings on 2026-08-20, consensus EPS -0.63 USD. Last quarter (2026-05-21) it missed with EPS -23.98 USD vs -23.245 USD est (-3.2%). It has beaten estimates in 0/1 recent quarters (0%). Trailing P/E -21.13.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does COAG next report earnings?
| Next earnings date | 2026-08-20 |
|---|---|
| Consensus EPS estimate | -0.63 USD |
| Revenue estimate | n/a |
COAG earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-21 | -23.98 USD | -23.245 USD | -3.2% | Miss |
Beat rate: 0/1 (0%) over reported quarters with consensus data.
COAG valuation and analyst view
| Trailing P/E | -21.13 |
|---|---|
| Trailing EPS | -2.32894 USD |
| Price / book | -7.65 |
| Dividend yield | 0.00% |
| Market cap | 0.10B |
| Analyst consensus | Buy (3 buy / 0 hold / 0 sell) |
| Avg price target | 45.13 USD |
Related research pages
Frequently asked questions
When is Hemab Therapeutics Holdings, Inc. Common Stock (COAG)'s next earnings date?
Hemab Therapeutics Holdings, Inc. Common Stock is next scheduled to report on 2026-08-20, with a consensus EPS estimate of -0.63 USD.
Did COAG beat earnings last quarter?
In its 2026-05-21 report, COAG posted EPS of -23.98 USD versus a -23.245 USD estimate — a miss of 3.2%.
What is COAG's earnings track record?
Over the last 1 reported quarters with consensus data, COAG beat estimates 0 times (0%).
What is COAG's current P/E ratio and EPS?
COAG trades at a trailing P/E of -21.13 on trailing EPS of -2.3289439786086827 USD.
What do analysts rate COAG?
Analyst consensus is "Buy" across 3 ratings (0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell). Average 12-month price target: 45.13 USD.